Natus Medical Incorporated
NTUS · NASDAQ
3/31/2022 | 12/31/2021 | 9/30/2021 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 15.66 | -1.65 | 0.54 | 1.57 |
| FCF Yield | 0.87% | 1.51% | 0.73% | 2.08% |
| EV / EBITDA | 80.16 | 69.61 | 53.51 | 62.94 |
| Quality | ||||
| ROIC | 0.45% | 0.41% | 1.37% | 0.85% |
| Gross Margin | 54.60% | 56.77% | 59.49% | 57.25% |
| Cash Conversion Ratio | 4.68 | 7.32 | 1.28 | 5.60 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.79% | -1.49% | -2.80% | -4.03% |
| Free Cash Flow Growth | -35.31% | 97.44% | -66.22% | -24.26% |
| Safety | ||||
| Net Debt / EBITDA | -7.18 | -6.04 | -3.82 | -3.71 |
| Interest Coverage | 13.64 | 17.73 | 25.74 | 10.82 |
| Efficiency | ||||
| Inventory Turnover | 0.75 | 0.82 | 0.64 | 0.73 |
| Cash Conversion Cycle | 140.64 | 128.90 | 161.28 | 147.27 |